Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology

GAITHERSBURG, Md. and SUZHOU, China, June 16, 2022 /PRNewswire/ — Sirnaomics Ltd. (“Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its…

Click here to view original post